In a research report issued today after market close, MLV & Co. analyst Arlinda Lee reiterated a Buy rating on shares of Halozyme Therapeutics, Inc.
In a research report sent to investors this morning, MLV analyst Arlinda Lee maintained a Buy rating on Halozyme Therapeutics (NASDAQ:HALO), and raised her …